Change search
ReferencesLink to record
Permanent link

Direct link
Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Linköping University, Department of Medical and Health Sciences. Linköping University, Faculty of Medicine and Health Sciences.
Karolinska Institute, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences.
Uppsala University, Sweden.
Show others and affiliations
2015 (English)In: Drug resistance updates, ISSN 1368-7646, E-ISSN 1532-2084, Vol. 21-22, 20-29 p.Article, review/survey (Refereed) Published
Abstract [en]

Although more traditionally associated with degradation and maintenance of protein homeostasis, the ubiquitin-proteasome system (UPS) has emerged as a critical component in the regulation of cancer cell growth and survival. The development of inhibitors that block the proteolytic activities of the proteasome have highlighted its suitability as a bona fide anti-cancer drug target. However, key determinants including the development of drug resistance and dose-limiting toxicity call for the identification of alternative components of the UPS for novel drug targeting. Recently the deubiquitinases (DUBS), a diverse family of enzymes that catalyze ubiquitin removal, have attracted significant interest as targets for the development of next generation UPS inhibitors. In particular, pharmacological inhibition of the proteasomal cysteine DUBs (i.e., USP14 and UCHL5) has been shown to be particularly cytotoxic to cancer cells and inhibit tumour growth in several in vivo models. In the current review we focus on the modes of action of proteasome DUB inhibitors and discus the potential of DUB inhibitors to circumvent acquired drug resistance and provide a therapeutic option for the treatment of cancer. (C) 2015 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
CHURCHILL LIVINGSTONE , 2015. Vol. 21-22, 20-29 p.
Keyword [en]
Cancer therapeutics; Small molecule inhibitors; Proteasome; Deubiquitinase; DUB; alpha, beta-Unsaturated ketones; Apoptosis
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-122221DOI: 10.1016/j.drup.2015.06.001ISI: 000362060500003PubMedID: 26183292OAI: diva2:864280

Funding Agencies|Cancerfonden; Vetenskapsradet; Radiumhemmets forskningsfonder; Barncancerfonden; Mary Beves Foundation; Alex and Eva Wallstroms Foundation; Ake Olssons Foundation

Available from: 2015-10-26 Created: 2015-10-23 Last updated: 2015-11-19

Open Access in DiVA

fulltext(4191 kB)5 downloads
File information
File name FULLTEXT01.pdfFile size 4191 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wang, XinLinder, StigD´arcy, Padraig
By organisation
Department of Medical and Health SciencesFaculty of Medicine and Health SciencesDivision of Drug Research
In the same journal
Drug resistance updates
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 5 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 57 hits
ReferencesLink to record
Permanent link

Direct link